Skip to content
Telehealth Graded

Search Telehealth Graded

Use arrow keys or Tab to browse. Enter opens a result. Escape closes search.

Enter a name or topic to search.

State guide

Nevada Medicaid and GLP-1s

Published by Telehealth Graded · Updated

The takeaway

Nevada Medicaid refuses GLP-1s for weight loss but allows Wegovy for heart risk and Zepbound for sleep apnea, both closed to anyone with diabetes.

Reading the state documents

Nevada writes its pharmacy policy into a manual, and the manual is unusually blunt. Weight loss on its own doesn't get you a GLP-1. Two other routes exist, and both of them are gated by a specialist: a cardiologist or vascular specialist for Wegovy, a documented sleep study for Zepbound. Each one is also closed to anyone who has diabetes.

1
document cited
8
sourced facts
1
primary source

What changed, and what the document says

  1. The general rule

    Not covered

    One clause, sitting inside the approval criteria for the whole class.

    “Medication is not being prescribed for weight loss in absence of T2DM indication;”

    Nevada Medicaid, Division of Health Care Financing and Policy — August 3, 2026

  2. Who signs for Wegovy

    Conditions apply

    Not a requirement to try a specialist. A requirement to involve one before the claim will pay.

    “Wegovy® must be prescribed by, or in consultation with, a cardiologist or vascular specialist; and”

    Nevada Medicaid, Division of Health Care Financing and Policy — August 3, 2026

  3. Diabetes disqualifies you here

    Conditions apply

    The exception exists for people who don't have diabetes. If you do, the manual sends you elsewhere.

    “Recipient must not have type 1 or type 2 diabetes. Recipients with type 1 or type 2 diabetes must have appropriate diabetic care with an alternative therapy as this indication is specific to non-diabetic recipients; and”

    Nevada Medicaid, Division of Health Care Financing and Policy — August 3, 2026

  4. Zepbound's one indication

    Conditions apply

    Sleep apnea, and the manual wants records rather than a diagnosis code.

    “Medication is being prescribed for moderate to severe obstructive sleep apnea (OSA) in adults with obesity, with OSA defined by one of the following [submission of records required]:”

    Nevada Medicaid, Division of Health Care Financing and Policy — August 3, 2026

  5. How long an approval lasts

    Conditions apply

    Six months on both exception routes, against a full year on the ordinary diabetes pathway.

    “Initial and recertification approval will be for six months.”

    Nevada Medicaid, Division of Health Care Financing and Policy — August 3, 2026

  6. What changed in August

    Context

    The whole revision, in the transmittal's own summary. It is about refills, not about who qualifies.

    “Updated refill quantity requirements for GLP-1s.”

    Nevada Medicaid, Division of Health Care Financing and Policy — August 3, 2026

  7. GLP-1s escape the 100-day rule

    Covered

    Nevada makes maintenance drugs go out in three-month fills. Diabetes GLP-1s are carved out of that.

    “Anticonvulsants, and thyroid preparations, and GLP-1s for diabetes are considered maintenance medications but are not required to be filled in a three-month (100-day) supply.”

    Nevada Medicaid, Division of Health Care Financing and Policy — August 3, 2026

  8. Read the page footer, not the cover

    Context

    The version is dated August 3, 2026, and the pages carrying the Wegovy and Zepbound criteria are footed January 5, 2026. One document, several ages.

    “These revisions were heard and approved through the Public Hearing process pursuant to Nevada Revised Statutes (NRS) 422.2369 on July 28, 2026, and became effective August 3, 2026.”

    Nevada Medicaid, Division of Health Care Financing and Policy — August 3, 2026

Telehealth in Nevada

Some providers pay us a commission when you sign up through our links, at no extra cost to you.

Which of these companies serve Nevada?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

23 of those lists name Nevada: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, The Virtual NP, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon, Peak Wellness, Sprout Health, Allara Health, MEDvidi, and Mixx Health & Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.

Sources

Source dates below are the dates printed on the documents.

  • Medicaid Services Manual Chapter 1200 — Prescribed Drugs — Nevada Medicaid, Division of Health Care Financing and Policy. the effective date stated in the transmittal letter dated July 28, 2026 — individual pages carry their own older footers, which the facts below name where it matters: August 3, 2026.

Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.

Browse 50 other state guides